Type to search

3Z Closes $2 Million Funding for Preclinical Development of Novel ADHD and Insomnia Therapeutics Identified by 3Z´s Zebrafish Drug Discovery Platform | Pharmtech Focus
Drug Development, Fundraising, Industry News, News
3Z Closes $2 Million Funding for Preclinical Development of Novel ADHD and Insomnia Therapeutics Identified by 3Z´s Zebrafish Drug Discovery Platform
Alisa Thoren June 21, 2022

3Z, a Reykjavik based drug discovery company is pleased to announce the closure of a $2 million funding round led by seasoned investors in pharmaceuticals and medical technology. The just closed funding will accelerate finalization of preclinical studies on ...

chat_bubble0 Comment visibility114 Views
Pharmtech Focus report on the latest Pharmtech news, bringing you up to the minute stories and features to stay ahead. Industry professionals and decision makers turn to us to keep up with and shape their industry.
Contact

For Media, Press and Advertising Enquiries please use our contact form or email address:


Contact

Email

Advertainment Media Ltd.
Pantiles Chambers
85 High Street
Tunbridge Wells
TN1 1XP

Copyright © Advertainment Media All Rights Reserved